Teladoc Health Reports Strong Q1 Revenue Growth Amid EPS Miss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy TDOC?
Source: seekingalpha
Teladoc Health Inc. saw its stock rise by 6.44% as it crossed above the 5-day SMA, reflecting positive market conditions. The company reported Q1 2026 revenue of $614 million, exceeding analysts' expectations of $611 million, despite a GAAP EPS loss of -$0.36, which missed expectations by $0.02. This revenue growth was driven by the expansion of its insurance market presence, now active in 30 states and Washington D.C., with over 6,000 credentialed providers, indicating strong potential for future revenue growth.
Despite the EPS miss, Teladoc's optimistic future outlook includes projected consolidated revenue for 2026 between $2.48 billion and $2.58 billion, with adjusted EBITDA expected to range from $267 million to $306 million. The management's confidence is particularly bolstered by the performance of BetterHelp's insurance business, which is expected to contribute significantly to revenue. However, ongoing challenges in profitability may influence investor sentiment moving forward.
The implications of Teladoc's performance suggest a resilient business model amid market fluctuations, with a focus on expanding its integrated care services. The company's ability to adapt and grow in the insurance market could position it favorably for future success, despite short-term profitability concerns.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TDOC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TDOC
Wall Street analysts forecast TDOC stock price to rise
15 Analyst Rating
3 Buy
12 Hold
0 Sell
Hold
Current: 6.960
Low
7.50
Averages
8.91
High
12.00
Current: 6.960
Low
7.50
Averages
8.91
High
12.00
About TDOC
Teladoc Health, Inc. provides virtual healthcare services. Its segments include Teladoc Health Integrated Care (Integrated Care) and BetterHelp. Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. Services in this segment are distributed on a B2B basis. BetterHelp segment includes direct-to-consumer mental health platform. The online counseling and therapy services are provided via its network of over 35,000 licensed clinicians leveraging its platform for Web, mobile app, phone, and text-based interactions. Its Teladoc Health family of brands, including Teladoc and BetterHelp, deliver access to advice and resolution for an array of healthcare needs. Its Telecare brand is a tech-enabled provider of specialist and allied health care via virtual delivery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mixed Earnings Reports from Multiple Companies
- Willis Towers Watson's Weak Performance: The insurer reported only 3% organic revenue growth in Q1, falling short of the 4.8% market expectation, leading to a 12% drop in stock price, despite adjusted earnings exceeding Wall Street forecasts, indicating potential growth challenges ahead.
- Hertz Partners with Uber: Hertz's stock surged about 18% following the announcement of a partnership with Uber, where its new Oro Mobility unit will support Uber's robotaxi initiative, with services expected to launch in the San Francisco Bay area later this year, marking a strategic move into autonomous driving.
- Altria's Earnings Beat Expectations: Altria reported adjusted earnings of $1.32 per share in Q1, surpassing the $1.25 consensus estimate, resulting in a stock increase of over 5%, while reaffirming its full-year adjusted earnings guidance, showcasing stability in the tobacco sector.
- Carrier Global's Strong Results: Carrier Global's Q1 adjusted earnings reached 57 cents, exceeding the expected 51 cents, with revenue of $5.34 billion surpassing the $5.01 billion consensus, leading to an 11% stock increase, reflecting robust performance in the building and refrigeration markets.
See More
FDA Proposes Exclusion of Weight Loss Drug Ingredients
- FDA Proposal: The U.S. Food and Drug Administration (FDA) has proposed to exclude Semaglutide and Tirzepatide from the 503B bulk list, limiting the compounding capabilities of outsourcing facilities, which may impact the market supply and accessibility of these drugs.
- Insufficient Clinical Need: The FDA stated that after reviewing available data, it found no clear clinical need to allow compounding of these drugs from raw ingredients, emphasizing patient safety and medical necessity, which could lead to restrictions on the use of related medications.
- Quality and Safety Concerns: The FDA has expressed concerns regarding the quality and safety of compounded weight-loss drugs, noting that these drugs are not reviewed by the FDA, which may pose risks such as improper storage, dosing errors, and counterfeit products, thereby affecting patient health.
- Market Reaction: Following the FDA proposal, shares of Eli Lilly and Novo Nordisk rose by 9% and 5%, respectively, indicating increased market confidence in the FDA-approved drugs from these companies, while Hims & Hers and Teladoc Health saw slight declines, reflecting market concerns over compounded medications.
See More
Significant Premarket Trading Moves by Multiple Companies
- Meta's CapEx Increase: Meta Platforms raised its full-year capital expenditure guidance to between $125 billion and $145 billion, causing a 9% drop in stock price due to heightened concerns over AI spending, which negatively impacts investor confidence.
- Eli Lilly's Strong Performance: Eli Lilly's first-quarter earnings and revenue exceeded analyst expectations, leading to an almost 8% stock increase, while the company raised its full-year sales outlook to between $82 billion and $85 billion, indicating robust market demand.
- Alphabet's Impressive Earnings: Alphabet reported first-quarter revenue of $109.9 billion, surpassing the $107.2 billion expected by analysts, resulting in a 7.4% stock increase, with Google Cloud revenue soaring 63% year-over-year, showcasing strong growth potential in its cloud business.
- Royal Caribbean's Solid Results: Royal Caribbean's first-quarter adjusted earnings came in at $3.60 per share, exceeding the $3.20 expected by analysts, and despite slightly missing revenue expectations, the stock rose 7%, reflecting market confidence in its financial health.
See More
Stock Futures Slip as Geopolitical Tensions Resurface
- Market Volatility: Stock futures slipped on Thursday morning as geopolitical tensions resurfaced, driving Brent crude to a four-year high, with investors reacting cautiously to reports of potential new military measures against Iran by the Trump administration, indicating market concerns over future uncertainties.
- Qualcomm's Strong Performance: Qualcomm (QCOM) shares surged 13% after reporting FQ2 adjusted EPS of $2.65, exceeding expectations, despite a 3% year-over-year revenue decline to $10.6 billion; growth in automotive (+38%) and IoT (+9%) segments demonstrated the company's resilience in diversifying markets.
- Carvana's Sustained Growth: Carvana (CVNA) shares rose 9% after reporting record revenue and adjusted EBITDA in Q1, with retail units sold climbing 40% to 187,393 and revenue jumping 52% to $6.43 billion, although rising costs led to margin declines, the company anticipates sequential growth in retail units and EBITDA in Q2.
- Alphabet's Strong Results: Alphabet (GOOG) shares advanced 7% after delivering a Q1 revenue increase of 22% year-over-year to $109.9 billion, with net income soaring 81% to $62.6 billion; the cloud segment's 63% revenue growth highlighted ongoing momentum driven by AI, and the company raised its quarterly dividend by 5% to $0.22 per share, reinforcing confidence in cash flow strength.
See More
Teladoc Health Q1 2026 Earnings Call Insights
- Financial Performance Exceeds Expectations: Teladoc reported Q1 2026 revenue of $614 million, surpassing analysts' expectations of $611 million, with adjusted EBITDA of $58 million, demonstrating the company's execution capabilities and market adaptability in integrated care.
- Insurance Market Expansion: The rollout in the U.S. insurance market has exceeded expectations, now live in 30 states and Washington D.C., with over 6,000 credentialed providers and more than 150 million covered lives, which is expected to provide strong support for future revenue growth.
- Optimistic Future Outlook: Teladoc anticipates 2026 consolidated revenue between $2.48 billion and $2.58 billion, with adjusted EBITDA ranging from $267 million to $306 million, reflecting management's confidence in future performance, particularly driven by BetterHelp's insurance business.
- Operational Challenges and Responses: Despite pressures on BetterHelp's direct-to-consumer business, management emphasized addressing these through insurance expansion and disciplined marketing spend, while ensuring adequate therapist capacity to meet demand, highlighting the company's focus on operational capabilities.
See More
Teladoc Health Reports Q1 EPS Miss and Revenue Beat
- Earnings Performance: Teladoc Health reported a Q1 GAAP EPS of -$0.36, missing expectations by $0.02, indicating ongoing challenges in profitability that may affect investor confidence.
- Revenue Growth: Despite the EPS miss, Teladoc's revenue reached $613.84 million, exceeding analyst expectations by $3.25 million, suggesting potential for growth in customer demand and market share.
- Future Guidance: The company's guidance for 2026 includes consensus estimates, reflecting management's confidence in future performance, although current profitability issues may influence long-term investor decisions.
- Market Reaction: Following the Q1 EPS miss, Teladoc's stock price declined, indicating market concerns about the company's short-term financial performance, which may lead investors to reassess their investment strategies.
See More
Mixed Earnings Reports from Multiple Companies
- Willis Towers Watson's Weak Performance: The insurer reported only 3% organic revenue growth in Q1, falling short of the 4.8% market expectation, leading to a 12% drop in stock price, despite adjusted earnings exceeding Wall Street forecasts, indicating potential growth challenges ahead.
- Hertz Partners with Uber: Hertz's stock surged about 18% following the announcement of a partnership with Uber, where its new Oro Mobility unit will support Uber's robotaxi initiative, with services expected to launch in the San Francisco Bay area later this year, marking a strategic move into autonomous driving.
- Altria's Earnings Beat Expectations: Altria reported adjusted earnings of $1.32 per share in Q1, surpassing the $1.25 consensus estimate, resulting in a stock increase of over 5%, while reaffirming its full-year adjusted earnings guidance, showcasing stability in the tobacco sector.
- Carrier Global's Strong Results: Carrier Global's Q1 adjusted earnings reached 57 cents, exceeding the expected 51 cents, with revenue of $5.34 billion surpassing the $5.01 billion consensus, leading to an 11% stock increase, reflecting robust performance in the building and refrigeration markets.
See More
FDA Proposes Exclusion of Weight Loss Drug Ingredients
- FDA Proposal: The U.S. Food and Drug Administration (FDA) has proposed to exclude Semaglutide and Tirzepatide from the 503B bulk list, limiting the compounding capabilities of outsourcing facilities, which may impact the market supply and accessibility of these drugs.
- Insufficient Clinical Need: The FDA stated that after reviewing available data, it found no clear clinical need to allow compounding of these drugs from raw ingredients, emphasizing patient safety and medical necessity, which could lead to restrictions on the use of related medications.
- Quality and Safety Concerns: The FDA has expressed concerns regarding the quality and safety of compounded weight-loss drugs, noting that these drugs are not reviewed by the FDA, which may pose risks such as improper storage, dosing errors, and counterfeit products, thereby affecting patient health.
- Market Reaction: Following the FDA proposal, shares of Eli Lilly and Novo Nordisk rose by 9% and 5%, respectively, indicating increased market confidence in the FDA-approved drugs from these companies, while Hims & Hers and Teladoc Health saw slight declines, reflecting market concerns over compounded medications.
See More
Significant Premarket Trading Moves by Multiple Companies
- Meta's CapEx Increase: Meta Platforms raised its full-year capital expenditure guidance to between $125 billion and $145 billion, causing a 9% drop in stock price due to heightened concerns over AI spending, which negatively impacts investor confidence.
- Eli Lilly's Strong Performance: Eli Lilly's first-quarter earnings and revenue exceeded analyst expectations, leading to an almost 8% stock increase, while the company raised its full-year sales outlook to between $82 billion and $85 billion, indicating robust market demand.
- Alphabet's Impressive Earnings: Alphabet reported first-quarter revenue of $109.9 billion, surpassing the $107.2 billion expected by analysts, resulting in a 7.4% stock increase, with Google Cloud revenue soaring 63% year-over-year, showcasing strong growth potential in its cloud business.
- Royal Caribbean's Solid Results: Royal Caribbean's first-quarter adjusted earnings came in at $3.60 per share, exceeding the $3.20 expected by analysts, and despite slightly missing revenue expectations, the stock rose 7%, reflecting market confidence in its financial health.
See More
Stock Futures Slip as Geopolitical Tensions Resurface
- Market Volatility: Stock futures slipped on Thursday morning as geopolitical tensions resurfaced, driving Brent crude to a four-year high, with investors reacting cautiously to reports of potential new military measures against Iran by the Trump administration, indicating market concerns over future uncertainties.
- Qualcomm's Strong Performance: Qualcomm (QCOM) shares surged 13% after reporting FQ2 adjusted EPS of $2.65, exceeding expectations, despite a 3% year-over-year revenue decline to $10.6 billion; growth in automotive (+38%) and IoT (+9%) segments demonstrated the company's resilience in diversifying markets.
- Carvana's Sustained Growth: Carvana (CVNA) shares rose 9% after reporting record revenue and adjusted EBITDA in Q1, with retail units sold climbing 40% to 187,393 and revenue jumping 52% to $6.43 billion, although rising costs led to margin declines, the company anticipates sequential growth in retail units and EBITDA in Q2.
- Alphabet's Strong Results: Alphabet (GOOG) shares advanced 7% after delivering a Q1 revenue increase of 22% year-over-year to $109.9 billion, with net income soaring 81% to $62.6 billion; the cloud segment's 63% revenue growth highlighted ongoing momentum driven by AI, and the company raised its quarterly dividend by 5% to $0.22 per share, reinforcing confidence in cash flow strength.
See More
Teladoc Health Q1 2026 Earnings Call Insights
- Financial Performance Exceeds Expectations: Teladoc reported Q1 2026 revenue of $614 million, surpassing analysts' expectations of $611 million, with adjusted EBITDA of $58 million, demonstrating the company's execution capabilities and market adaptability in integrated care.
- Insurance Market Expansion: The rollout in the U.S. insurance market has exceeded expectations, now live in 30 states and Washington D.C., with over 6,000 credentialed providers and more than 150 million covered lives, which is expected to provide strong support for future revenue growth.
- Optimistic Future Outlook: Teladoc anticipates 2026 consolidated revenue between $2.48 billion and $2.58 billion, with adjusted EBITDA ranging from $267 million to $306 million, reflecting management's confidence in future performance, particularly driven by BetterHelp's insurance business.
- Operational Challenges and Responses: Despite pressures on BetterHelp's direct-to-consumer business, management emphasized addressing these through insurance expansion and disciplined marketing spend, while ensuring adequate therapist capacity to meet demand, highlighting the company's focus on operational capabilities.
See More
Teladoc Health Reports Q1 EPS Miss and Revenue Beat
- Earnings Performance: Teladoc Health reported a Q1 GAAP EPS of -$0.36, missing expectations by $0.02, indicating ongoing challenges in profitability that may affect investor confidence.
- Revenue Growth: Despite the EPS miss, Teladoc's revenue reached $613.84 million, exceeding analyst expectations by $3.25 million, suggesting potential for growth in customer demand and market share.
- Future Guidance: The company's guidance for 2026 includes consensus estimates, reflecting management's confidence in future performance, although current profitability issues may influence long-term investor decisions.
- Market Reaction: Following the Q1 EPS miss, Teladoc's stock price declined, indicating market concerns about the company's short-term financial performance, which may lead investors to reassess their investment strategies.
See More
